Formosa Pharmaceuticals, Inc. (TPE:6838)
Taiwan flag Taiwan · Delayed Price · Currency is TWD
25.85
0.00 (0.00%)
At close: Mar 24, 2026

Formosa Pharmaceuticals Cash Flow Statement

Millions TWD. Fiscal year is Jan - Dec.
Fiscal Year
FY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Net Income
-83.57-201.01-321.96-406.27-400.88
Depreciation & Amortization
49.5641.8740.339.1537.63
Other Amortization
-0.410.240.250.1
Loss (Gain) From Sale of Assets
----0.2
Stock-Based Compensation
0.3636.22.422.59-
Provision & Write-off of Bad Debts
-7.82---
Other Operating Activities
-3.5425.0855.09-0.3938.79
Change in Accounts Receivable
--12.56-31.45-0.03-
Change in Inventory
-1.28-2.89---
Change in Accounts Payable
-75.9653.3924.5226.296.11
Change in Unearned Revenue
10.07-77.0141.1--
Change in Other Net Operating Assets
8.720.01-6.31-7.73-13.07
Operating Cash Flow
-95.64-128.68-196.04-346.15-331.13
Capital Expenditures
-10.01-7.27-2.17--0.22
Cash Acquisitions
--79.29--29.87-71.03
Sale (Purchase) of Intangibles
-31.88-0.98-0.08--14.85
Investment in Securities
20-387.27-673.98-158.75-
Other Investing Activities
-46.4-0.490.02-0.02-
Investing Cash Flow
-68.29-475.29-676.21-188.64-86.1
Long-Term Debt Repaid
-6.13-6.05-4.62-3.07-3.03
Net Debt Issued (Repaid)
-6.13-6.05-4.62-3.07-3.03
Issuance of Common Stock
-630.451,005503.54608
Other Financing Activities
---58.39-
Financing Cash Flow
-6.13624.4999.88558.86604.97
Foreign Exchange Rate Adjustments
-13.9420.65-10.2634.35-20.68
Net Cash Flow
-18441.08117.3758.42167.05
Free Cash Flow
-105.65-135.95-198.21-346.15-331.35
Free Cash Flow Margin
-1112.70%-94.83%-635.85%-26323.19%-1161.46%
Free Cash Flow Per Share
-0.69-0.96-1.60-3.29-3.58
Cash Interest Paid
0.490.570.760.990.08
Cash Income Tax Paid
0.060.883.130.072.89
Levered Free Cash Flow
-123.66-109.719.74-156.49-255.47
Unlevered Free Cash Flow
-123.36-109.3512.43-155.87-254.09
Change in Working Capital
-58.45-39.0527.8718.53-6.96
Source: S&P Global Market Intelligence. Standard template. Financial Sources.